Today, a Director at Epizyme (NASDAQ: EPZM), David Mott, bought shares of EPZM for $3.75M.
This recent transaction increases David Mott’s holding in the company by 6.44% to a total of $63.67 million.
See today’s analyst top recommended stocks >>
Based on Epizyme’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $12 million and GAAP net loss of $29.13 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $37.6 million. Currently, Epizyme has an average volume of 705.7K.
Based on 9 analyst ratings, the analyst consensus is Strong Buy with an average price target of $22.25, reflecting a 147.2% upside. Seven different firms, including Citigroup and Cowen & Co., currently also have a Buy rating on the stock.
David Mott’s trades have generated a 26.3% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Develops therapeutics for the treatment of patients with genetically defined cancers
